

Diaceutics PLC
("Diaceutics" or the "Company")

Transfer of Shares and Director/PDMR/PCA Shareholding

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, has today been informed that Delia Keeling, wife of Peter Keeling, the Chief Executive Officer and a PCA, has made the following transfers, of a total of 250,000 ordinary shares of £0.002 each in the Company ("Ordinary Shares") for nil consideration to the following persons:

- 100,000 Ordinary Shares to Robyn Keeling, wife of Ryan Keeling, the Chief Innovation Officer, also a PCA;
- 50,000 Ordinary Shares to Philip White, the Chief Financial Officer; and
- 100,000 Ordinary Shares to certain family friends.

As a result of these transfers, the beneficial holdings of the following directors and their connected parties in the Ordinary Shares of the Company are as follows:

- Peter Keeling, 17,252,049 Ordinary Shares, representing 20.52 % of the Company's issued share capital;
- Ryan Keeling, 2,990,643 Ordinary Shares, representing 3.56 % of the Company's issued share capital; and
- Philip White, 1,956,389 Ordinary Shares, representing 2.33 % of the Company's issued share capital.

Enquiries:

Diaceutics PLC

Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com
via Walbrook PR

Cenkos Securities plc (Nominated adviser and broker)

Callum Davidson / Giles Balleny
Michael Johnson (Sales)

+44 (0)207 397 8900

Walbrook PR

Anna Dunphy
Paul McManus

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Mob: +44 (0)7876 741 001
Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - the Diagnostic Network[®] provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform.

About DXRX - The Diagnostic Network[®]

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1 Details of the person discharging managerial responsibilities/person closely associated		
a.	Name	Delia Keeling
2 Reason for notification		
a.	Position/Status	PCA, wife of Peter Keeling

b.	Initial notification/ Amendment	Initial												
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor													
a.	Name	Diaceutics PLC												
b.	LEI	213800VEWQBB39ZB8J81												
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted													
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 ISIN: GB00BJQTGV64												
b.	Nature of the transaction	Transfer of Shares to four individual persons												
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>100,000</td> </tr> <tr> <td>Nil</td> <td>50,000</td> </tr> <tr> <td>Nil</td> <td>50,000</td> </tr> <tr> <td>Nil</td> <td>50,000</td> </tr> <tr> <td>Total</td> <td>250,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	100,000	Nil	50,000	Nil	50,000	Nil	50,000	Total	250,000
Price(s)	Volume(s)													
Nil	100,000													
Nil	50,000													
Nil	50,000													
Nil	50,000													
Total	250,000													
e.	Date of the transaction	6 April 2021												
f.	Place of the transaction	Outside a trading venue												

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014		
1	Details of the person discharging managerial responsibilities/person closely associated	
a.	Name	Robyn Keeling
2	Reason for notification	
a.	Position/Status	PCA, Wife of Ryan Keeling
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a.	Description of the	Ordinary shares of £0.002

	financial instrument, type of instrument					
	Identification Code	ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Receipt of shares from Delia Keeling				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>100,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	100,000
Price(s)	Volume(s)					
Nil	100,000					
e.	Date of the transaction	6 April 2021				
f.	Place of the transaction	Outside a trading venue				

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014						
1 Details of the person discharging managerial responsibilities/person closely associated						
a.	Name	Philip White				
2 Reason for notification						
a.	Position/Status	Chief Financial Officer				
b.	Initial notification/ Amendment	Initial				
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a.	Description of the financial instrument, type of instrument	Ordinary shares of £0.002				
	Identification Code	ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Receipt of shares from Delia Keeling				
c.	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>Nil</td> <td>50,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	Nil	50,000
Price(s)	Volume(s)					
Nil	50,000					
e.	Date of the transaction	6 April 2021				
f.	Place of the transaction	Outside a trading venue				

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHSSMSAAEFSELL